New Delhi: In a major deal that is set to reshape the Indian pharmaceutical landscape, Mankind Pharma has announced its acquisition of Bharat Serums & Vaccines (BSV) from Advent International. The transaction, valued at approximately Rs 13,630 crore, is expected to be finalized within the next three to four months, subject to regulatory approvals.
This strategic move will position Mankind Pharma as a dominant player in the Indian women’s health and fertility drug market. Additionally, the acquisition will provide the company with access to high-growth segments like critical care, leveraging BSV’s established R&D capabilities.
Founded in 1971 and headquartered in Mumbai, BSV is a well-known player in the development, manufacturing, and marketing of biological, biotech, and pharmaceutical formulations. The company’s strong product portfolio aligns well with Mankind Pharma’s existing offerings, promising significant synergies.
It is noteworthy that the acquisition was a competitive affair with Swedish private equity firm EQT and a consortium led by the Abu Dhabi Investment Authority (ADIA) also vying for BSV. The deal’s valuation is estimated to be between $1.5 billion and $2 billion.
With this acquisition, Mankind Pharma aims to expand its domestic footprint and strengthen its position in the highly competitive pharmaceutical market. The company is confident that the integration of BSV’s operations will enhance its overall performance and profitability.
